Prognostic value of p16 promoter hypermethylation in colorectal cancer: A meta-analysis

Cancer Investigation

Volumn 32, Issue 2, 2014, Pages 43-52

  Jiang, Wenjie ^a   Wang, Pei Ge ^b   Zhan, Yuzhu ^a   Zhang, Dongfeng ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

Colorectal cancer; Meta analysis; Methylation; P16 gene; Prognosis

Indexed keywords

PROTEIN P16;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DNA METHYLATION; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; SENSITIVITY ANALYSIS;

COLORECTAL NEOPLASMS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HUMANS; NEOPLASM PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84893277200     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357907.2013.861476     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J,Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90.
2. Sherr CJ,McCormick F.The RB and p53 pathways in cancer. Cancer Cell 2002;2(2):103-112.
3. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PÇ Baylin SB, Sidransky D. 5? CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1(7): 686-692.
4. Schuebel KE, Chen W, Cope L, Glockner SÇ Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, van Engeland M, Ting AH, Jair K, Yu W, Toyota M, Imai K, Ahuja N, Herman JG, Baylin SB. Comparing the DNA hypermethylome with genemutations in human colorectal cancer. PloSGenet 2007;3(9):1709-1723.
5. Tsai HÇ Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 2011;21(3):502-517.
6. Kim BN, Yamamoto H, Ikeda K, Damdinsuren B, Sugita Y, Ngan CY, Fujie Y, Ogawa M, Hata T, Ikeda M, Ohue M, Sekimoto M, Monden T, Matsuura N, Monden M. Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues. Int J Oncol 2005;26(5):1217-1226.
7. Mitomi H, Fukui N, Tanaka N, Kanazawa H, Saito T, Matsuoka T, Yao T. Aberrant p16((INK4a)) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity. J Cancer Res Clini Oncol 2010;136(2):323-331.
8. Liang JT, Chang KJ, Chen JÇ Lee CÇ Cheng YM, Hsu HÇ Wu MS, Wang SM, Lin JT, Cheng AL. Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. Oncology 1999;57(2):149-156.
9. Maeda K, Kawakami K, Ishida Y, Ishiguro K, Omura K, Watanabe G. Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival. Oncol Rep 2003;10(4): 935-938.
10. Barault L, Charon-Barra Ç Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot Ç Piard F.Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008;68(20):8541-8546.
11. Kim JÇ Choi JS, Roh SA, Cho DH, KimTW, KimYS. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann Surg Oncol 2010;17(7):1767-1776.
12. Wettergren Y, Odin E, Carlsson G, Gustavsson B.MTHFR,MTR, and MTRR polymorphisms in relation to p16INK4A hypermethylation in mucosa of patients with colorectal cancer. Mol Med (Cambridge, Mass) 2010;16(9-10):425-432.
13. Bihl MP, Foerster A, Lugli A, Zlobec I. Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing. J TranslMed 2012;10:173.
14. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, Herman JG, Capella G, Peinado MA. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001;19(2):299-304.
15. Ward RL, Cheong K, Ku SL, Meagher A, O'Connor T, Hawkins NJ. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 2003;21(20):3729-3736.
16. Gonzalez-Quevedo R, Garcia-Aranda Ç Moran A, De Juan Ç Sanchez-Pernaute A, Torres A, Diaz-Rubio E, Balibrea JL, Benito M, Iniesta P. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications. Int J Oncol 2004;24(2):349-355.
17. Sanz-Casla MT, Maestro ML, Vidaurreta M, Maestro Ç Arroyo M, Cerdan J. p16 gene methylation in colorectal tumors: correlation with clinicopathological features and prognostic value. Dig Dis 2005;23(2):151-155.
18. Ishiguro A, Takahata T, Saito M, Yoshiya G, Tamura Y, Sasaki M, Munakata A. Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer. J Gastroenterol Hepatol 2006;21(8):1334-1339.
19. Shen L, Catalano PJ, Benson AB 3rd, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007;13(20):6093-6098.
20. Miladi-Abdennadher I, Abdelmaksoud-Damak R, Ayadi L, Khabir A, Frikha F, Kallel L, Frikha M, Sellami-Boudawara T, Gargouri A, Mokdad-Gargouri R. Aberrant methylation of hMLH1 and p16INK4a in Tunisian patients with sporadic colorectal adenocarcinoma. Biosci Rep 2011;31(4):257-264.
21. Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: cohort study and literature review. Int J Cancer 2011;128(5):1080-1094.
22. Iida S, Kato S, Ishiguro M, Matsuyama T, Ishikawa T, Kobayashi H, Higuchi T, Uetake H, Enomoto M, Sugihara K. PIK3CA mutation and methylation influences the outcome of colorectal cancer. Oncol Lett 2012;3(3):565-570.
23. Han SW, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. Int J Cancer 2013;132(9):2209-2216.
24. Veganzones-de-Castro S, Rafael-Fernandez S, Vidaurreta-Lazaro M, de-la-Orden V, Mediero-Valeros B, Fernandez Ç Maestrode las Casas ML. p16 gene methylation in colorectal cancer patients with long-term follow-up. Rev Esp Enferm Dig 2012;104(3):111-117.
25. Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in metaanalyses. Available at: http://www.ohri.ca/programs/clinical epidemiology/oxford.asp.
26. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
27. Zhang T, Zhong W. Applied Methodology for Evidence-Based Medicine. Changsha, China: Central SouthUniversity Press, 2012, 163.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-188.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-560.
30. Brok J, Thorlund K, Gluud Ç Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008;61(8):763-769.
31. Wetterslev J,Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol 2009;9:86.
32. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trial 1997;18(6):580-593; discussion 661-586.
33. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 2008;37(5): 1148-1157.
34. Tobias A. Assessing the influence of a single study in the metaanalysis estimate. Stata Tech Bull 1999(47):15-17.
35. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis. Biometrics 2000;56(2):455-463.
36. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010;29(1):181-206.
37. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008;10(1):13-27.
38. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23(3):609-618.
39. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003;9(8):2898-2903.